2.29
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Manila Times
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - GlobeNewswire Inc.
What drives Neumora Therapeutics Inc. stock priceUnmatched profit growth - jammulinksnews.com
What analysts say about Neumora Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating - MSN
Neumora Therapeutics Inc. Stock Analysis and ForecastUnmatched market gains - jammulinksnews.com
Is Neumora Therapeutics Inc. a good long term investmentTriple-digit profit margins - jammulinksnews.com
What makes Neumora Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $5.00 - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
How Neumora Therapeutics Inc. stock reacts to Fed policy changesMarket Beating Strategy - Newser
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Mizuho raises Neumora Therapeutics stock price target on new drug candidate - Investing.com Canada
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
How Neumora Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Neumora Therapeutics (NMRA) Soars 33.02% on Drug Trial Advancement - AInvest
H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora begins phase 1 trial of schizophrenia drug NMRA-861 By Investing.com - Investing.com South Africa
Neumora Therapeutics’ Promising M4 PAM Program Drives Buy Rating with $18 Price Target - TipRanks
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 - The Manila Times
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):